Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-stage, Multi-center Concordance Study of Trophoblast Cell Surface Antigen 2 (TROP2) Normalized Membrane Ratio (NMR) in Non-Small Cell Lung Cancer Without Systemic Therapy

NCT07624318 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07624318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07624318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-stage, Multi-center Concordance Study of Trophoblast Cell Surface Antigen 2 (TROP2) Normalized Membrane Ratio (NMR) in Non-Small Cell Lung Cancer Without Systemic Therapy
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
August 13, 2026
Completion date
June 15, 2027
Enrollment
3,400 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer